Skip to content
51

diclofenac schmerzgel

Worth a look

Shows low returns (0.0%), but brand-locked demand (top 5 brands take 95% of clicks) keeps it on the watch list.

Market size 58Growth 21Conversion 85Competition 56Returns 100Price range 55Avg price 67Brand share 13Review moat 62Quality gap 23

Returns

Incredible0.0%

return rate — above 6% kills the launch gate

Conversion

Great9.6%

search→purchase rate — share of searches ending in a sale

Avg price

Good€14.09

avg listing price — sweet spot $15–$100

Review moat

Good1,009.41

avg incumbent reviews — the moat a new listing must climb

Market size

Good€452K

€452K/yr · 335K searches

Competition

Good52%

top-5 click share — leaders hold, buyers still browse

Price range

Good€7.09–€24.82

cheapest to priciest tracked listing — scored on the share inside $15–$100

Quality gap

Bad4.6★

avg incumbent rating — lower means beatable quality

Growth

Bad-8.6%

90-day search growth — must beat 0% to launch

Brand share

Bad95%

top-5 brand share — brand-locked demand

Competition

The top 5 products take 52% of clicks — established leaders, but buyers still shop beyond them.

Brands

8 falling

Sellers

30

Top-5 brand share

95%

Open market

3%

  • ratiopharm50%
  • AL Aliud Pharma23%
  • ADGC8%
  • Heumann8%
  • STADA5%
  • Voltaren2%
  • Open — no brand owns it (2 brands, 3%)

Product shelf

Each bubble is one product — market share against review moat; bubble size tracks estimated sales, color grades how beatable the incumbent looks.

0%4%€18K8%€36K12%€54K16%€72K1101001K10K Reviews — right = deep review moat Market share (90d) ≈ est. sales
Beatable (≤4.3★) Contested Strong incumbent (>4.7★)

All 27 tracked products in this niche — three views at once, no toggling.

Demand & seasonality

Weekly Amazon search volume, last 104 weeks — -8.6% search growth over the last 90 days.
30K20KSpike '24Spike '25Prime Day '25SepDecMarJunAugNovMarMay

Peak months: Aug, Sep · busiest ÷ quietest = 3.2×

Reviews

What buyers praise and complain about, mined from review topics.

What buyers love

Preis-Leistungs-Verhältnis67%

“Günstiger als Voltaren und genau gut”

Gelenkschmerzen33%

“Das Schmerzgel hält was es verspricht top 🔝 Ware”

What buyers complain about

beworben Vs Tatsächliches Produkt100%

“Warum soll ich mehr für den Wirkstoff bezahlen, nur weil er beworben wird (u. a.TV Printmedien)”

Top return reasons

Preis-Leistungs-Verhältnis25%
Funktionalität insgesamt25%
Gelenkschmerzen25%
Auslaufsicher25%